JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265698

Human IFITM3 (Fragilis) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

IFITM3 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and Insertion of the selection cassette in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
3 Images
Sanger Sequencing - Human IFITM3 (Fragilis) knockout HeLa cell line (AB265698)
  • Sanger seq

Unknown

Sanger Sequencing - Human IFITM3 (Fragilis) knockout HeLa cell line (AB265698)

Allele-3 : Insertion of the selection cassette in exon 1.

Sanger Sequencing - Human IFITM3 (Fragilis) knockout HeLa cell line (AB265698)
  • Sanger seq

Unknown

Sanger Sequencing - Human IFITM3 (Fragilis) knockout HeLa cell line (AB265698)

Allele-1 : 1 bp deletion in exon 1.

Sanger Sequencing - Human IFITM3 (Fragilis) knockout HeLa cell line (AB265698)
  • Sanger seq

Lab

Sanger Sequencing - Human IFITM3 (Fragilis) knockout HeLa cell line (AB265698)

Allele-2 : Insertion of the selection cassette in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and Insertion of the selection cassette in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265698-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265698 Human IFITM3 (Fragilis) knockout HeLa cell line", "number":"AB265698-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265698-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265698-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265698-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265698 Human IFITM3 (Fragilis) knockout HeLa cell line", "number":"AB265698-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265698-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265698 Human IFITM3 (Fragilis) knockout HeLa cell line", "number":"AB265698-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265698-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265698 Human IFITM3 (Fragilis) knockout HeLa cell line", "number":"AB265698-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
IFITM3
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The protein known as Fragilis also called Interferon-induced transmembrane protein 3 (IFITM3) plays a role in cellular defense mechanisms. Fragilis is approximately 15 kDa in mass. It is commonly expressed in cells of the immune system such as lymphocytes and can also be found in various tissues including the lungs spleen and thymus. This protein includes a chain of functional domains that interact with cellular membranes contributing to its protective roles on the cellular level.
Biological function summary

IFITM3 acts as an antiviral protein that disrupts the life cycle of viruses entering human cells. It is a part of a family of transmembrane proteins that block viral replication by inhibiting the fusion of viral membranes with endosomal membranes. The presence of Fragilis in respiratory epithelial cells is integral to the immune response against viral infections. The protein acts as a barrier to viruses like influenza providing an innate immune defense mechanism.

Pathways

The involvement of IFITM3 is central to the immune signaling pathways specifically the interferon signaling pathway. Upon viral infection interferons upregulate IFITM3 enhancing its antiviral activities. Other proteins like STAT1 and STAT2 mediate this regulation. Additionally IFITM3 aligns with the pathways regulating cell membrane integrity and remodeling highlighting its multi-functional role beyond just antiviral defense.

Research highlights the relevance of IFITM3 in conditions such as influenza and COVID-19. In both cases higher expression levels correlate with better prognosis. For instance variations in IFITM3 expression or genetic mutations can affect susceptibility to severe influenza. Connections with proteins such as MxA and other IFITM proteins can influence these disease processes. These connections make Fragilis a target of interest for understanding and potentially mitigating the severity of viral infections.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com